GRAIL filings document the public-company disclosures of a healthcare issuer developing and commercializing Galleri, a multi-cancer early detection test built on a targeted methylation-based platform. Its 8-K reports furnish operating and financial results, corporate presentations, clinical and regulatory updates, and other material events related to the company’s cancer detection business.
Regulatory filings also cover proxy governance, shareholder voting matters, board and leadership succession disclosures, emerging growth company status, and capital-structure activity. Recent records include securities purchase agreements, common stock and pre-funded warrant disclosures, resale registration-related materials, an at-the-market equity distribution agreement, and lease obligations, alongside exhibits and risk-oriented disclosures tied to GRAIL’s operations and financing needs.
ETRADE FINANCIAL CORPORATION reported insider share movements: a previously reported sale of 37,504 common shares by Robert P. Ragusa on 03/02/2026, and the issuer recorded restricted stock unit vestings of 1,891 shares on 03/04/2026 and 14,006 shares on 03/06/2026.
The filing lists the securities as Common Stock on NASDAQ and shows the shares were acquired upon vesting under the issuer's equity incentive plans for services rendered.
Joshua J. Ofman reported a proposed sale of 17,002 shares of common stock by notice on 03/02/2026, with an aggregate value of $852,847.77. The filing also lists restricted stock units that vested into 1,329 shares on 03/04/2026 and 5,502 shares on 03/06/2026 as issuances by the issuer for services rendered.
Shares outstanding were 40,990,388 as of 03/05/2026.
GRAIL, Inc. president Joshua J. Ofman reported a mix of equity awards and tax-related share sales. He received an award of 84,540 restricted stock units, which will vest in four substantially equal annual installments beginning on February 28, 2027, with each unit settling into one share of common stock upon vesting.
On March 2, 2026, an executing broker sold a total of 17,002 shares of common stock in automatic “sell-to-cover” transactions to satisfy withholding taxes upon award vesting, at weighted average prices of $51.7509 and $50.0853 per share. After these sales, Ofman directly owned 436,508 shares of common stock. His reported holdings were also adjusted to include 152 additional dividend shares received in connection with the GRAIL spin-off from Illumina.
GRAIL, Inc. reported that Chief Financial Officer Aaron Freidin received an award of 60,118 restricted stock units on February 27, 2026. These RSUs will vest in four substantially equal annual installments beginning on February 28, 2027, and each unit will settle into one share of common stock when vested.
On March 2, 2026, an executing broker carried out automatic sell-to-cover transactions totaling 9,573 shares of common stock at weighted average prices of $50.0853 and $51.8611 to cover withholding taxes tied to award vesting and share delivery. After these transactions, Freidin directly held 309,622 shares of GRAIL common stock.
GRAIL, Inc. director and Chief Executive Officer Robert P. Ragusa reported two automatic sell-to-cover transactions of common stock tied to equity award vesting. He disposed of 35,787 shares at an average price of $50.0853 and 1,717 shares at $51.8430 to cover withholding taxes.
After these tax-related sales, he continued to hold 650,525 shares of GRAIL common stock directly. The prices reported represent weighted average prices calculated by the executing broker for block trades executed in multiple transactions.
GRAL affiliate reported intent to sell 36,923 shares of common stock listed in a Form 144.
The shares were acquired upon vesting of restricted stock units awarded under the issuer's equity incentive plans on 02/28/2026. The excerpt also shows a prior sale of 13,000 shares on 12/03/2025 by Joshua J. Ofman for $1,300,000.
Aaron Freidin proposes to sell 23,076 shares of Common Stock acquired upon vesting of restricted stock units awarded under the issuer's equity incentive plans on 02/28/2026. The filing lists the issuer as ETRADE FINANCIAL CORPORATION.
The record shows a prior sale of 25,000 shares on 12/03/2025. The shares to be sold were recorded as acquired for services rendered on 02/28/2026.
GRAL Form 144 filing reports a securities sale notice by Robert Ragusa: 40,000 shares of common stock were sold on 12/03/2025.
The filing also records 74,873 shares acquired upon vesting of restricted stock units on 02/28/2026. Shares outstanding are listed as 40,341,120 as of 03/02/2026.
GRAIL, Inc. reported strong 2025 growth while remaining deeply loss-making and released landmark trial data for its Galleri multi-cancer blood test. Full-year revenue rose 17% to $147.2 million, driven by 26% growth in U.S. Galleri revenue to $136.8 million and more than 185,000 tests sold. Fourth-quarter revenue grew 14% to $43.6 million. Net loss narrowed sharply to $408.4 million from $2.03 billion, largely because 2024 included a large goodwill and intangible impairment; adjusted EBITDA improved to $(320.6) million. Cash, cash equivalents and short-term marketable securities totaled $904.4 million, which the company says supports operations into 2030.
The randomized NHS-Galleri trial in England did not meet its primary endpoint of a statistically significant reduction in combined Stage III–IV cancers, but showed a substantial reduction in Stage IV diagnoses, higher Stage I–II detection and a four-fold higher cancer detection rate when Galleri was added to standard screening. GRAIL completed its Galleri premarket approval submission to the FDA, finished analysis of the 35,000-participant PATHFINDER 2 study, and highlighted a new U.S. Medicare coverage pathway for multi-cancer early detection tests. Based on NHS-Galleri and PATHFINDER 2 results, the company plans to expand its U.S. field sales and medical teams.
GRAIL, Inc. reported strong 2025 growth while remaining deeply loss-making and released landmark trial data for its Galleri multi-cancer blood test. Full-year revenue rose 17% to $147.2 million, driven by 26% growth in U.S. Galleri revenue to $136.8 million and more than 185,000 tests sold. Fourth-quarter revenue grew 14% to $43.6 million. Net loss narrowed sharply to $408.4 million from $2.03 billion, largely because 2024 included a large goodwill and intangible impairment; adjusted EBITDA improved to $(320.6) million. Cash, cash equivalents and short-term marketable securities totaled $904.4 million, which the company says supports operations into 2030.
The randomized NHS-Galleri trial in England did not meet its primary endpoint of a statistically significant reduction in combined Stage III–IV cancers, but showed a substantial reduction in Stage IV diagnoses, higher Stage I–II detection and a four-fold higher cancer detection rate when Galleri was added to standard screening. GRAIL completed its Galleri premarket approval submission to the FDA, finished analysis of the 35,000-participant PATHFINDER 2 study, and highlighted a new U.S. Medicare coverage pathway for multi-cancer early detection tests. Based on NHS-Galleri and PATHFINDER 2 results, the company plans to expand its U.S. field sales and medical teams.
Illumina, Inc. filed an amended Schedule 13G showing its beneficial ownership in GRAIL, Inc. common stock has fallen to a minority position. Illumina reports beneficial ownership of 1,302,126 shares of GRAIL common stock, representing 3.2% of the outstanding class, with sole voting and dispositive power over all these shares.
The filing notes that as of December 31, 2025, Illumina beneficially owned 2,502,126 shares, and the 3.2% figure is based on 40,800,541 shares outstanding as of November 14, 2025. Illumina confirms it now holds 5% or less of GRAIL’s common stock.